Cynosure Group LLC Purchases New Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Cynosure Group LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, HoldingsChannel.com reports. The institutional investor acquired 17,736 shares of the biopharmaceutical company’s stock, valued at approximately $353,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CPRX. GAMMA Investing LLC grew its holdings in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares in the last quarter. nVerses Capital LLC bought a new stake in Catalyst Pharmaceuticals during the third quarter worth about $50,000. Larson Financial Group LLC grew its stake in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares in the last quarter. CWM LLC increased its holdings in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $70,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Trading Up 1.9 %

NASDAQ:CPRX opened at $22.34 on Friday. The stock’s 50-day moving average is $21.21 and its 200-day moving average is $18.69. The stock has a market cap of $2.66 billion, a P/E ratio of 18.93, a price-to-earnings-growth ratio of 3.26 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.00 and a 1-year high of $24.27.

Analysts Set New Price Targets

Several research firms recently issued reports on CPRX. Citigroup increased their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Truist Financial lifted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.